Bayer Slumps After $2.25 Billion Roundup Trial Loss
- Stock decline brings losses since Monsanto deal to almost 70%
- Verdict by Philadelphia jury is largest so far on weed killer
This article is for subscribers only.
Bayer AG shares slumped after the German conglomerate was ordered to pay about $2.3 billion to a former Roundup user who blamed the weed killer for his cancer.
The verdict by a Philadelphia jury is the largest so far in five years of litigation over the herbicide. The stock fell as much as 5.7% in Frankfurt trading, and it’s down almost 70% since Bayer acquired Roundup’s maker Monsanto in 2018.